Abstract:Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease. Chronic bronchitis (CB) and emphysema are typical phenotypes of COPD. We investigated the proteomics and metabolic profiles in COPD patients with phenotypes of CB and emphysema.Methods: Serum from 30 healthy controls (HCs), 30 patients with CB, and 30 cases with emphysema was evaluated using Tandem Mass Tag proteomics analysis and liquid chromatography-mass spectrometry-based metabolomics. Differentially expressed proteins (DEPs) and differentially expressed metabolites (DEMs) were identified for further bioinformatics analysis.Findings: Expression of 114 DEPs and 194 DEMs was uniquely altered in COPD patients, compared with that in HCs. Also,36 DEPsand 99 DEMs in the serum from CB cases showed a significant degree of differential expression compared with those with emphysema. Integrated analysis of proteomics and metabolomics revealed propanoate metabolism, ferroptosis, and protein digestion and absorption to be enriched in the DEPs and DEMs of COPD patients compared with that in HCs. Importantly, propanoate metabolism was enriched in CB versus HCs, whereas ferroptosis was enriched in emphysema versus HCs. In COPD patients versus HCs, DEPs and DEMs were enriched in the same pathways: glycolysis/gluconeogenesis, nitrogen metabolism, propanoate metabolism, and fructose and mannose metabolism.Interpretation: A combination of proteomics analysis and metabolomics assays can provide new and deeper insights into COPD pathogenesis, as well as developing suitable and targeted interventions.Clinical Trial Registration Details: Registered in China with the Clinical Trial Registration Center (ChiCTR1900022271).Funding Information: This work was supported by 1•3•5 Project for Disciplines of Excellence, West China Hospital of Sichuan University (2018HXFH017), National Key Research and Development Program in China (2016YFC0903600), and National Natural Science Foundation of China (31871157, 81830001 and 82100047).Declaration of Interests: The authors declare no conflicts of interest.Ethics Approval Statement: The research protocol complied with the principles of the Declaration of Helsinki 1964 and its later amendments. The research protocol was approved by the Ethics Committee of the West China Hospital of Sichuan University of China (Sichuan, China). All study participants provided written informed consent.

Stratification of pre-COPD by lung volume indices creates distinct proteomic profiles in COPDGene cohort

Identifying targets for COPD treatment through gene expression analyses.

Basal gene expression by lung CD4+ T cells in chronic obstructive pulmonary disease identifies independent molecular correlates of airflow obstruction and emphysema extent

Integrating Genetics, Transcriptomics, and Proteomics in Lung Tissue to Investigate COPD

2D cross-omics integrated enrichment analysis reveals insights into COPD pathogenesis

Proteomics and metabolomics profiling reveal panels of circulating diagnostic biomarkers and molecular subtypes in stable COPD

Serum metabolomics analysis of patients with chronic obstructive pulmonary disease and 'frequent exacerbator' phenotype

Reduced Frequencies of Foxp3+GARP+ Regulatory T Cells in COPD Patients Are Associated with Multi-Organ Loss of Tissue Phenotype

Lung Tissue Multi-Layer Network Analysis Uncovers the Molecular Heterogeneity of COPD

Gene Expression Profiling in Patients with Chronic Obstructive Pulmonary Disease and Lung Cancer

Genetic Regulation of Gene Expression in the Lung Identifiescst3andcd22as Potential Causal Genes for Airflow Obstruction

Integrated Analysis of Metabolomics and Proteomics Datasets Reveals Insights Into the Mechanism of Chronic Obstructive Pulmonary Disease With Chronic-Bronchitis and Emphysema Phenotypes

Identification of biomarkers associated with clinical severity of chronic obstructive pulmonary disease

Proteomic networks and related genetic variants associated with smoking and chronic obstructive pulmonary disease

Screening and Identification of Tissue-Infiltrating Immune Cells and Genes for Patients with Emphysema Phenotype of COPD

Proteomics-based biomarkers in chronic obstructive pulmonary disease.

Identifying Chronic Obstructive Pulmonary Disease from Integrative Omics and Clustering in Lung Tissue.

Identification of Proteomic Signatures in Chronic Obstructive Pulmonary Disease Emphysematous Phenotype

Altered serum metabolomics in COPD: analysis of the SPIROMICS cohort

Circulating biomarkers of airflow limitation across the life span

Serum Proteomic Profiling in Patients with Chronic Obstructive Pulmonary Disease